LITTLE ROCK, Ark. (AP) — An attorney representing the state of Arkansas says a subsidiary of Johnson & Johnson should be penalized over the risks associated with the anti-psychotic drug Risperdal.Jurors heard opening statements Tuesday in Arkansas' lawsuit against Janssen Pharmaceuticals Inc. In January, Janssen settled with Texas for $158 million in a similar suit, but the company did not admit liability or fault.The state says 250,000 Risperdal prescriptions were issued for Arkansas Medicaid patients between 2002 and 2006. The state wants Janssen fined for each of the prescriptions — seeking a total award of $1.25 billion to $2.5 billion.Janssen attorney James Simpson disputed studies that said the company hid information about the safety of the drug. He told the jury that the company did not deceive doctors or release inaccurate information.